vTv Therapeutics Inc. (VTVT): Cash & Equivalents
$88.93M
As of 2025-12-31
$86.64M
As of 2026-06-30
+94.3%
3-year compound annual growth
+73.0%
5-year compound annual growth
+0.1%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $88.93M | +142.0% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $36.75M | +289.0% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $9.45M | -22.1% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $12.13M | -9.6% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $13.41M | +133.4% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $5.75M | +223.4% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $1.78M | +5.6% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $1.68M | -85.7% | 2020-02-21, Balance as of period end |
| 2017-12-31 | $11.76M | -77.2% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $51.51M | -41.5% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $88.00M | n/m | 2017-02-24, Balance as of period end |
| 2014-12-31 | $1.38M | +27.1% | 2017-02-24, Balance as of period end |
| 2013-12-31 | $1.09M | n/a | 2016-03-04, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $88.93M | +142.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare VTVT, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗